Most Read News

The drug is the generic alternative of the Vitamin K1 Injection produced by Hospira Inc and is indicated in the treatment of Vitamin K deficiency-related coagulation disorders.

TMB continues to focus on retail and MSME customer franchise, particularly in south India, where it enjoys a strong regional franchis

The renewal premium, as per the company, was up by 12.90% YoY to ₹14,680.30 Crore versus ₹13,003.20 Crore.

Here are some of the stocks that may see significant price movement today: Axis Bank, Tech Mahindra, SBI Card & Payments.

The work entails technical and management assistance for the proposed Phase-II SILO rail connectivity project at the Lakhanpur Area of MCL, as stated in the firm's regulatory filing.

EBITDA margin narrowed by 250 basis points to 13.5%, due to increased input and operating costs.

The bank announced that its Net Interest Margin witnessed an improvement of 4 basis points to 3.97% on a sequential basis.

The company’s revenue for the quarter registered a growth of 12.40% on a sequential basis to ₹2,982.40 Crore as compared to ₹2,653 Crore.

The fundraising may be executed in one or more tranches using QIP, rights issues, or any other permissible route under regulatory guidelines.

The drug will be manufactured at Lupin's facility in Nagpur, India, and the company has announced plans for a near-term launch in the U.S. market.